Sponsors (2)
The bill makes it much easier for patients—especially in rural and underserved areas—to get psychiatric and controlled‑substance care by expanding cross‑state telehealth and standardizing rules, but it raises substantial safety, cost, oversight, and market‑concentration risks that depend on how safeguards, enforcement, and insurer/provider responses play out.
Patients with mental‑health conditions, opioid use disorder, and other chronic conditions — especially in rural and underserved areas — can obtain FDA‑approved psychiatric medications and controlled‑substance prescriptions more quickly via a single telehealth visit or cross‑state telepsychiatry.
Telehealth clinicians and companies can simplify compliance (e.g., designate company practice location, avoid multiple state DEA registrations, and use licensure reciprocity where requirements are substantially similar), making it easier for clinicians to provide telemedicine across state lines.
Pharmacies are prohibited from refusing valid telehealth prescriptions solely because they were issued via telehealth, and malpractice coverage is clarified for cross‑state telepsychiatry, reducing some barriers and legal ambiguity for patients and clinicians.
Patients and communities face increased risk of inappropriate prescribing, diversion, and broader public‑health harms because expanded telehealth prescribing of controlled substances reduces traditional in‑person checks unless monitoring and safeguards are substantially strengthened.
Extensive staffing, accreditation, monitoring, workforce and compensation rules increase operational costs and administrative burden for telehealth providers, likely raising prices, reducing availability of low‑cost services, and constraining workforce flexibility (hurtful to smaller providers and part‑time clinicians).
The Act limits states' ability to impose stricter public‑health or licensing protections and shifts oversight across jurisdictions, reducing state control over professional discipline and public‑safety measures and creating potential litigation over preemption.
Based on analysis of 5 sections of legislative text.
Expands telehealth authority to prescribe and dispense certain FDA‑approved non‑narcotic controlled substances for mental health, enables telemedicine dispensing without extra state registrations, and permits limited cross‑state telepsychiatry with federal preemption.
Official title: To amend the Controlled Substances Act to modify requirements relating to the prescription of controlled substances by means of the internet, and for other purposes.
Introduced January 9, 2026 by Neal Patrick Dunn · Last progress January 9, 2026
Allows licensed psychiatrists and other authorized clinicians to prescribe certain FDA‑approved non‑narcotic controlled substances for mental health conditions after telehealth evaluations and to dispense controlled substances via telemedicine without additional state registrations; permits telehealth providers to list a telehealth entity as their principal place of business; creates a limited cross‑state practice pathway for psychiatrists whose malpractice insurance and licensure meet specified conditions; and federally preempts state laws to the extent they would block these activities. The law also defines key terms (approved mental‑health controlled substances, exempt entities, telehealth entity thresholds) and sets conditions for entities that merge with telehealth providers.